ASCO GU 2017: A Therapeutic Update on the Management of Patients with Prostate Cancer

Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncologists, radiation oncologists, uro-oncologists, and other HCPs responsible for the diagnosis, treatment, or management of patients with prostate cancer.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Explain the molecular targets of prostate cancer
  2. Describe the highlights on prostate cancer that were presented at the 2017 Genitourinary Cancers Symposium
  3. Develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with prostate cancer

FACULTY

Karen Knudsen, PhD
Director of the Sidney Kimmel Cancer Centre
Professor and Chair of the Department of Cancer Biology
Thomas Jefferson University
Philadelphia, PA

Robert Bristow, MD, PhD, FRCPC
Clinician-Scientist and Professor, Radiation Oncology & Medical Biophysics
Princess Margaret Cancer Centre
University of Toronto
Toronto, Canada

Wm Kevin Kelly, DO
Director, Division of Solid Tumour Oncology
Associate Director of Clinical Research
Leader Prostate Cancer Programme
Thomas Jefferson University
Philadelphia, PA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Karen Knudsen, PhD

Consultant/Advisor: CellCentric, sanofi-aventis U.S. LLC

Grant/Research Support: CellCentric, Celgene Corporation

Stock ownership: Pfizer Inc.

Robert Bristow, MD PhD FRCPC

Grant/Research Support: AstraZeneca, GenomeDx

Wm Kevin Kelly, DONo financial relationships to disclose

Non-faculty: Julie Huang; Sandy Breslow; Alison Kemp; Leah Johnson; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sanofi Genzyme.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
04/03/2017
Course expires: 
04/02/2018
Rating: 
4

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
04/03/2017
Course expires: 
04/02/2018
Please login or register to take this course.